- Home
- SENEB vs VTYX Comparison
SENEB vs VTYX Comparison
Compare SENEB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | VTYX |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 713.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SENEB | VTYX |
|---|---|---|
| Price | $110.27 | $13.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 447.0 | ★ 4.3M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.84 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $71.47 | $0.78 |
| 52 Week High | $124.94 | $25.00 |
Technical Indicators
Market Signals| Indicator | SENEB | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 75.60 |
| Support Level | $109.56 | $7.08 |
| Resistance Level | $115.00 | $15.34 |
| Average True Range (ATR) | 0.39 | 0.68 |
| MACD | -1.65 | 0.56 |
| Stochastic Oscillator | 9.78 | 81.42 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.